Cordis-X Invests in Adient Medical, Developer of Fully Absorbable IVC Filter

June 14, 2022—Cordis-X announced an $11.5 million Series F investment in Adient Medical, maker of a next-generation absorbable inferior vena cava (IVC) filter that provides protection against pulmonary embolisms.

Adient’s device is designed to avoid the risks of perforation, migration, fracture, and thrombosis that have been the focus of the FDA-mandated PRESERVE study of six commercially available IVC filters.

Adient has obtained investigational device exemption approval for both a 510(k) study for therapeutic indication and a premarket approval application for a prophylactic indication, that potentially may increase the addressable patient population and may establish a new standard of care for patients with short-term pulmonary embolism risk from immobilizing surgery, trauma, or other medical procedures.

Jeremy Durack, MD, who authored a seminal paper exposing the safety concerns with metal filters in 2012, is Chief Clinical Officer of Cordis-X. Dr. Durack has served as a member of Adient’s Scientific Advisory Board and will now join Adient as the Chief Clinical Officer. He will work collaboratively with Adient Chief Medical Officer Joseph Steele, MD, and Matthew Johnson, MD, who will lead Adient’s upcoming pivotal study, on clinical validation of Adient’s technology. Dr. Johnson is also Principal Investigator of the PRESERVE study.

Cordis-X stated that it is an innovation accelerator that identifies and advances differentiated technologies with the potential to expand the Cordis portfolio with solutions that respond to unmet needs in cardiovascular health.

Cordis Executive Chairman and Cordis-X CEO Duke Rohlen stated in the press release, “Effective IVC filtering remains one of the toughest problems in the cardiovascular space. If left in the body, metal filters can create safety risks that increase dramatically over time. Retrievable filters partially address these concerns, but retrieval procedures are costly, complex, and frequently delayed. Adient addresses the root cause of these issues through a filter that serves its purpose, then simply vanishes without the need for additional intervention.”